[16]
There may have been an assumption in
GlaxoSmith 2003
that the rule was 5 experts per issue, but there was no specific conclusion on this point. As will be discussed, the reference to that part of the
Eli Lilly 2003
decision is not a clear unequivocal ruling on the point.